VIDAZA® as treatment for MDSa at diagnosis

Treating patients with VIDAZA® at diagnosis can help improve overall survival, increase independence from RBC transfusions and delay progression to AML.1, 2

Learn more
Eliminating age as a factor in treatment choice for adult patients

VIDAZA® is the only agent proven to improve overall survival vs. CCR in MDSa patients over 75 years old.4

Learn more
The importance of treatment duration

Continued treatment with VIDAZA® can increase response quality in responders.3 Find out why it’s important to maintain treatment until disease progression.

Learn more
7 days of VIDAZA®

VIDAZA® is given 7 days in a row2. Learn more about dosing, and help your patients understand their first 7 days of treatment.

Learn more
  1. #
  2. #
  3. #
  4. #

VIDAZA® Treatment for MDSa

VIDAZA® is the first drug treatment to significantly prolong overall survival and thus alter the natural history of myelodysplastic syndromes.1

VIDAZA® Treatment for AMLb

VIDAZA® is changing the pathway in the treatment of AML, a fatal haematological malignancy with limited treatment options and poor survival outcomes.2

VIDAZA® for the Treatment of Patients with MDSa or AMLb

VIDAZA® is the first drug treatment to significantly prolong overall survival in MDSa patients and thus alter the natural history of the disease.1 VIDAZA® is also changing the pathway in the treatment of AMLb, 2, a fatal haematological malignancy with limited treatment options and poor survival outcomes. About VIDAZA® >

  1. Fenaux P et al. Lancet Oncology 2009; 10:223-232.
  2. VIDAZA® Summary of Product Characteristics, 2011.
  3. Silverman LT et al. Cancer. 2011. 117:2697-2702.
  4. Seymour JF et al. Crit Rev Oncol Hematol. 2010. 76:218-227
a. MDS-specific Indication

VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:

  • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
  • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:

Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ≥20% to <30% as AML patients.

Disclaimer

This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.